Patents by Inventor Rudolph E. Tanzi

Rudolph E. Tanzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9938263
    Abstract: There are provided, inner alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 10, 2018
    Assignees: The General Hospital Corporation, The Regents of the University of California
    Inventors: Rudolph E. Tanzi, Steven L. Wagner, Soan Cheng, William C. Mobley
  • Publication number: 20180093967
    Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant A? peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L? is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
    Type: Application
    Filed: October 30, 2015
    Publication date: April 5, 2018
    Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
  • Patent number: 9403815
    Abstract: The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)-(C)-(D)??(I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: August 2, 2016
    Assignees: The Regents of the University of California, The General Hospital Corporation
    Inventors: Steven L. Wagner, Soan Cheng, William C. Mobley, Rudolph E. Tanzi
  • Publication number: 20160024073
    Abstract: There are provided, imer alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Inventors: Rudolph E. TANZI, Steven L. WAGNER, Soan CHENG, William C. MOBLEY
  • Publication number: 20150218259
    Abstract: The invention relates to antibodies that bind cross-linked amyloid ? oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.
    Type: Application
    Filed: August 6, 2014
    Publication date: August 6, 2015
    Applicant: The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Robert Moir, Rudolph E. Tanzi
  • Publication number: 20140377267
    Abstract: The invention relates to antibodies that bind cross-linked amyloid ? oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.
    Type: Application
    Filed: August 6, 2014
    Publication date: December 25, 2014
    Applicant: The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Robert Moir, Rudolph E. Tanzi
  • Publication number: 20130165416
    Abstract: The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)—(C)-(D)??(I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
    Type: Application
    Filed: June 24, 2011
    Publication date: June 27, 2013
    Inventors: Steven L. Wagner, Soan Cheng, William C. Mobley, Rudolph E. Tanzi
  • Publication number: 20130022994
    Abstract: The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid ?.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 24, 2013
    Applicant: The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Rudolph E. Tanzi, Giuseppina Tesco
  • Patent number: 8273543
    Abstract: The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid ?.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: September 25, 2012
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Giuseppina Tesco
  • Publication number: 20120114635
    Abstract: The invention relates to antibodies that bind cross-linked amyloid ? oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.
    Type: Application
    Filed: June 7, 2011
    Publication date: May 10, 2012
    Applicant: The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Robert Moir, Rudolph E. Tanzi
  • Publication number: 20120058935
    Abstract: The invention features antimicrobial compositions comprising ?-amyloid peptides, oligomers, and analogs thereof, and methods of using them for the prevention or treatment of an infection.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 8, 2012
    Applicant: The General Hospital Corporation
    Inventors: Robert Moir, Rudolph E. Tanzi
  • Publication number: 20110177543
    Abstract: The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid ?.
    Type: Application
    Filed: August 24, 2010
    Publication date: July 21, 2011
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: RUDOLPH E. TANZI, GIUSEPPINA TESCO
  • Publication number: 20100311726
    Abstract: The present invention relates to novel uses for a family of small molecules, Differentiation-Inducing Factors (DIFs). It has been discovered that DIFs surprisingly can alter the metabolic processing of amyloid precursor protein (APP) and in turn reduce the level of secreted A?. The metabolic processing of other ?-secretase substrates normally present in cells (Notch and APLP1) is not affected when treated with DIF. The invention provides methods for reducing A? production in mammalian cells that express APP by administering DIF-I, DIF-2, DIF-3, a functionally equivalent analog and or any combination thereof. The invention also provides methods for treating and/or preventing Alzheimer's disease by preferentially reducing A? production.
    Type: Application
    Filed: July 16, 2008
    Publication date: December 9, 2010
    Inventors: Michael Myre, Wilma Wasco, Rudolph E. Tanzi
  • Patent number: 7781177
    Abstract: The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid ?.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 24, 2010
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Giuseppina Tesco
  • Publication number: 20100113570
    Abstract: Methods for the use of uncompetitive NMDA receptor antagonist(s) in inhalational anesthesia are provided herein.
    Type: Application
    Filed: April 23, 2009
    Publication date: May 6, 2010
    Applicants: The General Hospital Corporation, D/B/A MASSACHUSETTS GENERAL HISPITAL
    Inventors: Zhongcong Xie, Rudolph E. Tanzi
  • Publication number: 20080118499
    Abstract: The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid ?.
    Type: Application
    Filed: July 11, 2007
    Publication date: May 22, 2008
    Applicant: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Giuseppina Tesco
  • Patent number: 7326540
    Abstract: The invention relates to methods and products for inhibiting caspase activation-induced A? accumulation. The invention is useful for diagnosing, preventing, and treating A?-accumulation-associated disorders, such as Alzheimer's disease.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: February 5, 2008
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Giuseppina Tesco, Young Ho Koh
  • Patent number: 7045531
    Abstract: The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions. Methods and compositions for treatment of conditions caused by amyloidosis, A?-mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: May 16, 2006
    Assignee: The General Hospital Corporation
    Inventors: Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi
  • Patent number: 6890727
    Abstract: The disclosed invention relates to assays for detecting and quantifying A? peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of A? peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of A? peptides from biological fluids are taught.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: May 10, 2005
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Ashley I. Bush, Robert D. Moir
  • Patent number: 6887983
    Abstract: The present invention relates, in general, to presenilin 2 proteolytic fragments. In particular, the present invention relates to a purified 20 kDa presenilin 2 C-terminal fragment (PS2-CTF); purified nucleic acid molecules coding for the 20 kDa PS2-CTF protein; cells containing the nucleic acid molecules; non-human organisms containing the nucleic acid molecule; antibodies having specific binding affinity to the 20 kDa PS2-CTF; hybridomas containing the antibodies; methods of detecting 20 kDa PS2-CTF in a sample; diagnostic kits; methods for screening compounds that inhibit proteolytic processing of presenilin 2 in a cell, isolated compounds that inhibit proteolytic processing of presenilin 2 in a cell, and a method of inhibiting apoptotic cell death by preventing proteolytic cleavage of presenilin 2 at a cleavage site which generates a 20 kDa C-terminal fragment.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: May 3, 2005
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Tae-Wan Kim